$8.06
0.8611.94%
Last update: Nov 6, 4:17 PM
Immix Biopharma Inc (IMMX) Stock Price, Quote, News & History
IMMXNASDAQ
BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.
You can purchase shares of Immix Biopharma (NASDAQ:IMMX) through any online brokerage.
Other companies in Immix Biopharma’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Immix Biopharma has a consensus price target of $24.00.
The stock price for Immix Biopharma (NASDAQ: IMMX) is $7.9897 last updated November 6, 2026 at 4:17 PM EST.
There are no upcoming dividends for Immix Biopharma.
Immix Biopharma does not have any upcoming earnings scheduled.
There is no upcoming split for Immix Biopharma.
Immix Biopharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific...
